Bone Cancer - Pipeline Review, H2 2013

Description: Bone Cancer - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, ‘Bone Cancer - Pipeline Review, H2 2013’, provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. Bone Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Cancer.
- A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Bone Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Bone Cancer
Bone Cancer Therapeutics under Development by Companies
Bone Cancer Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Bone Cancer Therapeutics - Products under Development by Companies
Bone Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Bone Cancer Therapeutics Development
Debiopharm Group
Aileron Therapeutics, Inc.
Hawthorn Pharmaceuticals, Inc.
Virobay Inc.
Kalosbios Pharmaceuticals, Inc.
Bone Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Debio-0719 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KB-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Angiotensin 1-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATSP-7041 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MN-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Astrogorgiadiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Cancer Therapeutics - Drug Profile Updates
Bone Cancer Therapeutics - Dormant Products
Bone Cancer - Product Development Milestones
Featured News & Press Releases
Oct 22, 2012: Eleison Enrolls First Patient In Phase II Trial Of Cisplatin For Pediatric Bone Cancer
Sep 12, 2012: Indian Supreme Court Asks Novartis To Scale Down Price Of Cancer Drug Glivec
Aug 07, 2012: Philips And Celsion Announce FDA Clearance To Commence Phase II Study Of ThermoDox And MR-Guided HIFU In Bone Cancer
Mar 02, 2012: Niiki Pharma To Begin Phase I Trial Of NKP-2235
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
Jun 22, 2011: Celsion's ThermoDox Featured In Special Issue Of The Open Nanomedicine Journal
Jun 06, 2011: Merck And ARIAD Announce Presentation Of Results Of Phase III SUCCEED Trial At ASCO Annual Meeting
Jul 11, 2007: Amgen and Daiichi Sankyo Announce Agreement For Denosumab In Japan
Mar 14, 2002: Amgen Signs Multi-Year Agreement With International Oncology Network for Aranesp, Neulasta and NEUPOGEN
Mar 14, 2002: Amgen Signs Multi-Year Agreement With US Oncology for Aranesp, Neulasta and NEUPOGEN
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bone Cancer, H2 2013
Products under Development for Bone Cancer - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Debiopharm Group, H2 2013
Aileron Therapeutics, Inc., H2 2013
Hawthorn Pharmaceuticals, Inc., H2 2013
Virobay Inc., H2 2013
Kalos Bios Pharmaceuticals, Inc., H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Bone Cancer Therapeutics - Drug Profile Updates
Bone Cancer Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Bone Cancer, H2 2013
Products under Development for Bone Cancer - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 25

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2647752/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name**: Bone Cancer - Pipeline Review, H2 2013
- **Web Address**: http://www.researchandmarkets.com/reports/2647752/
- **Office Code**: SCD2FP8D

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title**: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
- **First Name**: ___________________________  **Last Name**: ___________________________
- **Email Address**: *
- **Job Title**: ___________________________
- **Organisation**: _________________________
- **Address**: ____________________________
- **City**: _______________________________
- **Postal / Zip Code**: ____________________
- **Country**: ____________________________
- **Phone Number**: ________________________
- **Fax Number**: _________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World